ELIZABETH FINSNESS: Open Payments
NPI 1649877101 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,221 in 222 payments from 21 companies in 2025. Trend: 2023 $7,905 · 2024 $4,277 · 2025 $5,221
Food & beverage: $4,971Education: $250
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 34 | $676 |
| Regeneron Healthcare Solutions, Inc. | 11 | $621 |
| UCB, Inc. | 19 | $576 |
| GENZYME CORPORATION | 15 | $502 |
| ABBVIE INC. | 31 | $465 |
| PFIZER INC. | 18 | $374 |
| Galderma Laboratories, L.P. | 14 | $352 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 13 | $313 |
| Arcutis Biotherapeutics, Inc. | 17 | $236 |
| Botanix SB Inc | 11 | $225 |
Products named: DUPIXENT, TREMFYA, Bimzelx, NEMLUVIO, SKYRIZI, CIBINQO, Zoryve, SOFDRA.
Industry payments across TX — which companies pay providers there.
